Note 5. Balance Sheet Components

Cash Equivalents and Available-for-sale Securities

Cash equivalents and available-for-sale securities consisted of the following (in thousands):


	September 30, 2019
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Money market funds	$	16,381	$	—	$	—	$	16,381
Corporate bonds		28,083		23		(1)		28,105
Commercial paper		40,868		—		(3)		40,865
Government bonds		46,579		17		—		46,596
Total cash equivalents and available-for-sale securities	$	131,911	$	40	$	(4)	$	131,947
Classified as:
Cash equivalents							$	44,450
Available-for-sale securities								87,497
Total cash equivalents and available-for-sale securities							$	131,947


	December 31, 2018
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Money market funds	$	25,390	$	—	$	—	$	25,390
Corporate bonds		8,997		—		(8)		8,989
Commercial paper		59,730		—		—		59,730
Government bonds		33,423		—		(29)		33,394
Total cash equivalents and available-for-sale securities	$	127,540	$	—	$	(37)	$	127,503
Classified as:
Cash equivalents							$	80,883
Available-for-sale securities								46,620
Total cash equivalents and available-for-sale securities							$	127,503

Available-for-sale securities - current held as of September 30, 2019 and December 31, 2018 had contractual maturities of less than one year. There were no material realized gains or realized losses on available-for-sale securities for the periods presented. The Company has not experienced any material credit losses on its investments.

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	September 30,		December 31,
	2019		2018
Laboratory equipment	$	3,006	$	2,533
Furniture and computer equipment		487		338
Leasehold improvements		800		67
Total property and equipment		4,293		2,938
Less: accumulated depreciation and amortization		(2,559)		(2,077)
Property and equipment, net	$	1,734	$	861

Accrued Expenses and Other Payables

Accrued expenses and other payables consisted of the following (in thousands):


	September 30,		December 31,
	2019		2018
Accrued clinical and research related expenses	$	6,420	$	7,781
Accrued employee related expenses		3,480		2,726
Accrued professional service fees		376		61
Other		210		595
Total accrued expenses and other payables	$	10,486	$	11,163